BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The ENEST1st study was, therefore, conducted to evaluate the efficacy of nilotinib in achieving deeper molecular responses in a large patient population of newly diagnosed patients with CML who were BCR–ABL1 positive (Hochhaus et al. 2016a).